Exagen Inc. Announces Select Preliminary 2025 Financial Results
MWN-AI** Summary
Exagen Inc. (Nasdaq: XGN), a prominent player in autoimmune testing, has reported select preliminary unaudited financial results for the fourth quarter and full year of 2025, showcasing solid growth. The Carlsbad, California-based company anticipates total revenue between $16 million to $17 million for Q4 and between $66 million to $67 million for the entire year, marking year-over-year increases of 19% to 20%. Notably, Exagen's AVISE CTD test volume reached approximately 136,000 to 137,000 with a trailing 12-month average selling price (ASP) estimated between $441 to $445.
John Aballi, the President and CEO, expressed satisfaction with Exagen's performance despite facing unexpected challenges related to ASP in the latter half of the year. He emphasized the company's achievements in revenue growth driven by both increased volume and ASP, alongside notable enhancements made to the AVISE platform. With a year-end cash position of $32 million—up $10 million from 2024—Exagen remains well-positioned to invest in innovation and maintain its strategic focus on transforming autoimmune disease care.
While the preliminary results are promising, Exagen cautions that the financial closing procedures are ongoing, meaning final figures may vary from the current estimates. The results thus far align with the company's prior guidance and demonstrate its commitment to addressing the complexities of autoimmune conditions.
Exagen's flagship product, the AVISE® CTD, is crucial for accurate and timely diagnoses of complex autoimmune diseases, reinforcing the company’s mission dedicated to improving patient outcomes. As Exagen continues to navigate the landscape of autoimmune diagnostics, stakeholders are reminded of the risks and challenges inherent in the healthcare sector and the potential impacts on future performance.
MWN-AI** Analysis
Exagen Inc. (Nasdaq: XGN) has recently announced its preliminary unaudited financial results for 2025, showcasing a robust growth trajectory in the autoimmune diagnostics market. With total revenue expected between $66 million to $67 million, marking a year-over-year increase of 19% to 20%, the trends signal positive momentum for investors. The increase in AVISE CTD test volume, which grew by 11% to approximately 137,000 tests, further demonstrates the demand for Exagen's offerings.
One of the noteworthy highlights is the growth in average selling price (ASP), which increased by at least $30 year-over-year, suggesting enhanced market acceptance and value perceived by clinicians in Exagen’s diagnostic solutions. The reported year-end cash and equivalents rising to $32 million, up from $22 million in the previous year, indicates strong cash flow management and positions Exagen well for future innovations and business opportunities.
However, potential investors should remain cautious. The company mentions "unexpected ASP headwinds" faced in the latter part of 2025, which could signify pricing pressures or challenges in reimbursement negotiations that might impact profit margins moving forward. It is also essential to note the company's forward-looking statements are subject to risks, including reimbursement delays and the crucial need for ongoing market acceptance.
Considering these factors, investors might view Exagen as a mid-to-long-term holding, capitalizing on its growth potential in a niche healthcare market. Still, given the uncertainties highlighted, a prudent approach would be to monitor Exagen’s upcoming finalized financial statements and listen for updates regarding reimbursement policies. Investors should look for sustained volume and price growth in the first half of 2026 as indicators of continued momentum before making any significant investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CARLSBAD, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced select preliminary unaudited financial results for the fourth quarter and year ended December 31, 2025, in line with prior financial guidance.
Select Preliminary Unaudited 2025 Results
| Revenue | |||
| Three Months Ended December 31, 2025 | Twelve Months Ended December 31, 2025 | ||
| Total Revenue | $16M to $17M | $66M to $67M | |
| Year-Over-Year Growth | 17% to 24% | 19% to 20% |
| Other | |
| Twelve Months Ended December 31, 2025 | |
| AVISE CTD Volume | 136,000 to 137,000 |
| AVISE CTD Trailing 12-month (TTM) average selling price | $441 to $445 |
| Year-end cash and cash equivalents | $32M |
The select preliminary unaudited financial results reported today represent:
- Record full year 2025 revenue, an increase of at least 19% over 2024
- AVISE CTD trailing 12-month (TTM) ASP expansion by at least $30 compared to 2024
- AVISE CTD test volume growth of at least 13,000, an 11% increase over 2024
- Year-end cash and cash equivalents of $32 million, a $10 million increase over 2024
“I am pleased to report the completion of another strong year for Exagen in which we’ve continued to make substantial progress in building a great company; a testament to continued execution across our commercial, scientific, and operational teams,” said John Aballi, President and CEO. “Based upon our preliminary results, we delivered significant topline growth, driven by both volume and ASP expansion, despite unexpected ASP headwinds in the second half of the year. We also strengthened our scientific and commercial teams and subsequently launched our first enhancements to the AVISE platform in several years, with more on the horizon. Our strong cash position and disciplined approach provide the flexibility to continue to invest in innovation and advance our strategy to change the standard of care in autoimmune disease while pursuing our goal of operating a profitable company.”
Cautionary Note Regarding Select Preliminary Unaudited Financial Results
Exagen is providing the above select preliminary unaudited financial information and results of operations as of and for the three months and year ended December 31, 2025, based on currently available information. The company’s financial closing procedures with respect to the estimated financial data provided above are not yet complete. These procedures often result in changes to accounts. The company’s independent registered public accounting firm has not audited, reviewed, compiled or performed any procedures with respect to the select preliminary unaudited financial information and, accordingly, our independent registered public accounting firm does not express an opinion or any other form of assurance with respect thereto. As a result, the company’s final results may vary from the preliminary results presented above. Management undertakes no obligation to update or supplement the information provided above until it releases its audited financial statements prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP) for the year ended December 31, 2025.
About Exagen
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s syndrome earlier and with greater accuracy. Exagen’s laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen’s goals, strategies and ambitions; the potential utility and effectiveness of Exagen’s services and testing solutions, additional enhancements to the AVISE platform; potential shareholder value and growth and profitability; preliminary financial information for 2025. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 11, 2025, Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the SEC on November 4, 2025 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Jeff Black, Chief Financial Officer
Exagen Inc.
ir@exagen.com
FAQ**
What specific factors contributed to Exagen Inc. XGN's impressive year-over-year revenue growth of 19% to 20% for 2025, as reported in the preliminary results?
How does Exagen Inc. XGN plan to address the unexpected ASP headwinds faced in the second half of 20to maintain growth in 2026?
Can you elaborate on the anticipated enhancements to the AVISE platform mentioned by Exagen Inc. XGN, and how they are expected to impact future revenue streams?
What are the key risks and uncertainties that could potentially affect Exagen Inc. XGN's ability to sustain its market acceptance and achieve profitability in the coming years?
**MWN-AI FAQ is based on asking OpenAI questions about Exagen Inc. (NASDAQ: XGN).
NASDAQ: XGN
XGN Trading
3.08% G/L:
$3.4015 Last:
603,728 Volume:
$3.40 Open:
